Key Highlights
- Shares of MGRX skyrocketed more than 129% Monday following an SEC disclosure that CEO Jacob Cohen was awarded 500,000 bonus shares.
- Cohen transferred an additional 200,000 shares into The Tiger Cub Trust, an entity under his control, increasing the trust’s holdings to 805,000 shares.
- Daily trading volume exploded to more than 107 million shares versus a three-month average of approximately 208,000.
- The stock plummeted 54.51% during Friday’s session and remains down 78.11% for the year.
- Wall Street analysts maintain a “Strong Sell” consensus with no current price targets available.
Shares of Mangoceuticals (MGRX) surged over 129% during Monday’s trading session after regulatory documents filed with the SEC disclosed that Chief Executive Officer Jacob Cohen was granted 500,000 shares as bonus compensation.
In the same regulatory filing, Cohen moved 200,000 shares into The Tiger Cub Trust, which operates under his authority, pushing the trust’s combined position to 805,000 shares. The dual transactions detailed in the filing triggered significant attention from market participants.
The dramatic Monday rally came on the heels of a brutal Friday session that saw the stock collapse by 54.51%. Despite Monday’s gains, MGRX shares remain deeply negative, down 78.11% year-to-date and off 96.59% over the trailing twelve-month period.
Trading activity reached extraordinary levels, with over 107 million shares exchanging hands. This represents a dramatic acceleration compared to the stock’s typical three-month daily average volume of roughly 208,000 shares.
According to MarketBeat information, the most recent recorded closing price stands at approximately $2.33 per share from late October 2025. No analyst price targets are currently published for the stock.
Legal Action and Intellectual Property Initiatives
Beyond Monday’s filing activity, Mangoceuticals has been active on multiple corporate fronts. The company revealed it initiated civil litigation against Clarity Ventures, Inc., a former technology services partner, pursuing damages that exceed $73 million. The complaint alleges significant failures in technology services delivery and platform development obligations.
Regarding intellectual property expansion, Mangoceuticals submitted a PCT international patent application in February covering MGX-0024, described as an antiviral additive technology designed for incorporation into animal feed and drinking water systems. The filing occurred on February 26, 2026, and seeks comprehensive global patent coverage.
Commercial Activities
The company’s $99 monthly injectable testosterone replacement therapy (TRT) subscription service has shown promising performance metrics. Company executives highlighted 336% month-over-month revenue growth since mid-December alongside a 54% reduction in customer acquisition expenses.
Mangoceuticals expanded its product portfolio with the November 2025 launch of MangoRx Direct and PeachesRx Direct platforms. These services offer patient access to GLP-1 weight management medications including Zepbound and Wegovy, with monthly pricing beginning around $499 on a direct cash-pay model.
Notwithstanding these operational developments, analyst coverage remains sparse and overwhelmingly negative. MarketBeat data shows one Sell rating with zero Buy or Hold recommendations currently assigned to the equity.
The analyst consensus classification sits at “Strong Sell,” and no major investment firms have published rating changes, upgrades, downgrades, or fresh price targets in recent months.
The latest available closing price on record stands at approximately $2.33 per share from late October 2025.
